Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
Slika profila

Stjepan Balić

2828

Stjepan

Balić

dr. sc.

nije evidentirano
Naziv Akcije
(EMPA-REG OUTCOME Investigators) Verma, Subodh ; ...Tušek, Srećko ; Mirošević, Gorana, Goldoni, Vesna ; Jurišić-Eržen, Dubravka ; Balaško, Annemarie ; Balić, Stjepan ; Drvodelić- Šunić, Ema ; Canecki Varžić, Silvija ; ... Zinman, Bernard Influence of Microvascular Disease on Cardiovascular Events in Type 2 Diabetes // Journal of the American College of Cardiology, 73 (2019), 21; 2780-2782. doi: 10.1016/j.jacc.2019.03.002
(EMPA-REG OUTCOME Investigators) Wanner, Christoph ; ... Tušek, Srećko ; Mirošević, Gorana ; Goldoni, Vesna ; Jurišić- Eržen, Dubravka ; Balaško, Annemarie ; Balić, Stjepan ; Drvodelić- Šunić, Ema ; Canecki Varžić, Silvija ; ..Groop, Per-Henrik Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME Trial // Journal of the American Society of Nephrology, 29 (2018), 11; 2755-2769. doi: 10.1681/asn.2018010103
(EMPA-REG OUTCOME Investigators) Zinman, Bernard ; ... Tušek, Srećko ; Mirošević, Gorana ; Goldoni, Vesna ; Jurišić- Eržen, Dubravka ; Balaško, Annemarie ; Balić, Stjepan ; Drvodelić- Šunić, Ema ; Canecki Varžić, Silvija ; ... et al. Empagliflozin in women with type 2 diabetes and cardiovascular disease – an analysis of EMPA-REG OUTCOME® // Diabetologia (Berlin), 61 (2018), 7; 1522-1527. doi: 10.1007/s00125-018-4630-2
(EMPA-REG OUTCOME Investigators) Wanner, Christoph ; ... Tušek, Srećko ; Mirošević, Gorana, Goldoni, Vesna ; Jurišić-Eržen, Dubravka ; Balaško, Annemarie ; Balić, Stjepan ; Drvodelić- Šunić, Ema ; Canecki Varžić, Silvija ; ...Zinman, Bernard ; Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease // Circulation, 137 (2018), 2; 119-129. doi: 10.1161/circulationaha.117.028268
(EMPA-REG OUTCOME Investigators) Fitchett, David ; ...Tušek, Srećko ; Mirošević, Gorana, Goldoni, Vesna ; Jurišić-Eržen, Dubravka ; Balaško, Annemarie ; Balić, Stjepan ; Drvodelić- Šunić, Ema ; Canecki Varžić, Silvija ; ... ; Inzucchi, Silvio E ; Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial // European heart journal, 39 (2017), 5; 363-370. doi: 10.1093/eurheartj/ehx511
(EMPA-REG OUTCOME Investigators) Zinman, Bernard ; ... ; Tušek, Srećko ; Mirošević, Gorana, Goldoni, Vesna ; Jurišić-Eržen, Dubravka ; Balaško, Annemarie ; Balić, Stjepan ; Drvodelić- Šunić, Ema ; Canecki Varžić, Silvija ; ... et al. Empagliflozin and cerebrovascular events in patients with type 2 diabetes mellitus at high cardiovascular risk // Stroke, 48 (2017), 5; 1218-1225. doi: 10.1161/strokeaha.116.015756
(EMPA-REG OUTCOME Investigators) Kaku, Kohei ; ... Tušek, Srećko ; Mirošević, Gorana, Goldoni, Vesna ; Jurišić-Eržen, Dubravka ; Balaško, Annemarie ; Balić, Stjepan ; Drvodelić- Šunić, Ema ; Canecki Varžić, Silvija ; ...Woerle, Hans-Juergen Empagliflozin and Cardiovascular Outcomes in Asian Patients With Type 2 Diabetes and Established Cardiovascular Disease ― Results From EMPA-REG OUTCOME<sup>®</sup> ― // Circulation journal, 81 (2017), 2; 227-234. doi: 10.1253/circj.cj-16-1148
(EMPA-REG OUTCOME Investigators) Wanner, Christoph ; ...Tušek, Srećko ; Mirošević, Gorana, Goldoni, Vesna ; Jurišić-Eržen, Dubravka ; Balaško, Annemarie ; Balić, Stjepan ; Drvodelić- Šunić, Ema ; Canecki Varžić, Silvija ; ...Zinman, Bernard Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes // The New England journal of medicine, 375 (2016), 4; 323-334. doi: 10.1056/nejmoa1515920
Rahelić, Dario ; Altabas, Velimir ; Bakula, Miro ; Balić, Stjepan ; Balint, Ines ; Bergman Marković, Biserka ; Bičanić, Nenad ; Bjelinski, Igor ; Božikov, Velimir ; Canecki Varžić, Silvija et al. Hrvatske smjernice za farmakološko liječenje šećerne bolesti tipa 2 // Liječnički vjesnik : glasilo Hrvatskoga liječničkog zbora, 138 (2016), 1-2; 1-21
Liberati-Čizmek, A-M. ; Bakula, M. ; Balić, S. Melatonin - novo lice moderne dijabetologije // Knjiga sažetaka 76. dani dijabetologa. 2015. str. ---
nije evidentirano
nije evidentirano